Mink therapeutics to present data update from allogeneic inkt cells in solid tumors at sitc 2023

New york, sept. 27, 2023 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced plans to unveil updated clinical and translational data, along with insights on agent-797's distinct mechanism of action in solid tumors. a poster will be presented at the society for immunotherapy of cancer's (sitc) 38th annual meeting on november 1-5, 2023.
INKT Ratings Summary
INKT Quant Ranking